BIIB catalyst calendar

BIOGEN INC.

Upcoming catalysts
24
Cash runway
Cash generating
Phase 3 programs
49

BIOGEN INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus on October 20, 2026. There are 24 upcoming events on record.

BIOGEN INC. generates cash from operations, so a burn-based runway figure does not apply.

Across 413 concluded trials, 77% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 20, 2026 A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus Trial Milestone Phase 2/Phase 3
December 1, 2026 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) Trial Milestone Phase 3
February 2, 2027 A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants Trial Milestone Phase 1
May 20, 2027 A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis Trial Milestone Phase 3
May 26, 2027 A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) Trial Milestone Phase 4
May 31, 2027 A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) Trial Milestone Phase 3
August 7, 2027 A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation Trial Milestone Phase 3
September 24, 2027 A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) Trial Milestone Phase 3
September 30, 2027 A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) Trial Milestone Phase 1
November 16, 2027 A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia Trial Milestone Phase 3
January 31, 2028 A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old Trial Milestone Phase 2
February 10, 2028 A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation Trial Milestone Phase 2
June 19, 2028 A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo Trial Milestone Phase 1
June 23, 2028 A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam Trial Milestone Phase 3
November 28, 2028 A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) Trial Milestone Phase 3
June 26, 2029 A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus Trial Milestone Phase 3
July 27, 2029 A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec Trial Milestone Phase 3
January 28, 2030 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) Trial Milestone Phase 3
June 4, 2030 A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old Trial Milestone Phase 1
November 14, 2031 A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec Trial Milestone Phase 1
December 31, 2031 A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) Trial Milestone Phase 3
May 3, 2032 A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) Trial Milestone Phase 3
January 23, 2034 A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) Trial Milestone Phase 1/Phase 2
July 28, 2034 A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Trial Milestone Phase 3

Track BIIB alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open BIIB in the tracker

Recent history

DateEventTypePhase
September 30, 2026 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus Trial Milestone Phase 3
September 27, 2026 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus Trial Milestone Phase 3
July 30, 2026 A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) Trial Milestone Phase 3
July 29, 2026 Quarterly results filed (8-K) Earnings —
July 1, 2026 Quarterly results filed (8-K) Earnings —
June 24, 2026 A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old Trial Milestone Phase 1
June 22, 2026 Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa Trial Milestone Phase 3
May 14, 2026 8-K filed: Material agreement, Acquisition completed, Reg FD disclosure Corporate —
May 1, 2026 A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 Trial Milestone Phase 1
April 29, 2026 Quarterly results filed (8-K) Earnings —
April 6, 2026 Quarterly results filed (8-K) Earnings —
March 31, 2026 8-K filed: Material agreement, Other event Corporate —
March 11, 2026 8-K filed: Leadership change Corporate —
March 11, 2026 A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age Trial Milestone Phase 2
March 10, 2026 A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways Trial Milestone Phase 1
March 9, 2026 A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 Trial Milestone Phase 2
March 5, 2026 A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy Adults Trial Milestone Phase 1
February 11, 2026 8-K filed: Leadership change, Other event Corporate —
February 10, 2026 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) Trial Milestone Phase 2
February 6, 2026 Quarterly results filed (8-K) Earnings —
January 14, 2026 Quarterly results filed (8-K) Earnings —
October 30, 2025 Quarterly results filed (8-K) Earnings —
October 16, 2025 A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55 Trial Milestone Phase 1
October 14, 2025 Quarterly results filed (8-K) Earnings —
October 9, 2025 A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND) Trial Milestone Phase 4
August 19, 2025 A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55 Trial Milestone Phase 1
July 31, 2025 Quarterly results filed (8-K) Earnings —
July 8, 2025 Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Trial Milestone Phase 3
July 7, 2025 Quarterly results filed (8-K) Earnings —
May 12, 2025 8-K filed: Other event Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.